scholarly journals AB040. SOH21AS090. Managing refractory cardiac arrhythmias in structurally abnormal hearts via thoracoscopic cardiac denervation: a case series

2021 ◽  
Vol 5 ◽  
pp. AB040-AB040
Author(s):  
Darragh John Rice ◽  
Joseph McLoughlin ◽  
Donna Eaton
2014 ◽  
Vol 9 (9-10) ◽  
pp. 357-357
Author(s):  
Zoran Bakotic ◽  
Ante Anic ◽  
Marin Bistirlic ◽  
Albino Jovic

2007 ◽  
Vol 17 (8) ◽  
pp. 738-748 ◽  
Author(s):  
LUKE Y.-J. WANG ◽  
ALLISON K. ROSS ◽  
JENNIFER S. LI ◽  
STEPHANIE M. DEARMEY ◽  
JOANNE F. MACKEY ◽  
...  

2020 ◽  
Author(s):  
Husam M. I. Salah ◽  
Jawahar L. Mehta

Abstract Introduction: The 2019 novel coronavirus disease (COVID-19) is a current pandemic. Cardiovascular manifestations of COVID-19 have been described in many studies; however, no studies have examined the prevalence and characterizations of cardiac arrhythmias among patients with COVID-19 infection. The aim of this meta-analysis was to examine the prevalence of cardiac arrhythmias among patients with COVID-19 infection.Method: PubMed, Google Scholar, and ResearchGate databases were searched for relevant articles from inception until June 14, 2020. Inclusion criteria were: 1) Cohort studies or case series studies; 2) Study population included individuals with confirmed COVID-19 infection; 3) Arrhythmic events were reported in the study. All other studies were excluded. MedCalc software was used to analyze the pooled data. The random-effect model was utilized to obtain the prevalence of arrhythmia among the included patients and its 95% confidence interval. Cohran's Q and I2 index were used for heterogeneity measurements. The main planned outcome was the prevalence of arrhythmia among patients with COVID-19 infection.Results: Thirteen studies with a total of 2861 patients met our inclusion criteria. The prevalence of arrhythmia among patients with COVID-19 infection was 8.1% (95% CI [6.10, 10.37]). 82.8% of the patients who had arrhythmia has severe illness (95% CI [70.916, 92.124]).Conclusion: The prevalence of arrhythmias among patients with COVID-19 infection is 8.1%, which is much higher than in the general population (2.35%).


2020 ◽  
Vol 2 ◽  
pp. 100010
Author(s):  
Marie-Jacqueline Reisener ◽  
Jennifer Shue ◽  
Alexander P Hughes ◽  
Andrew A Sama ◽  
Ronald G Emerson ◽  
...  

2020 ◽  
Vol 7 ◽  
Author(s):  
Srinivasan Murali ◽  
Nicolas Brugger ◽  
Francisco Rincon ◽  
Manoj Mashru ◽  
Stéphane Cook ◽  
...  

Background: Cardiac arrhythmias are very common but underdiagnosed due to their transient and asymptomatic nature. An optimization of arrhythmia detection would permit to better treat patients and could substantially reduce morbidity and mortality. The SmartCardia ScaAI wireless patch is a novel CE IIa approved, single-lead electrocardiographic (ECG) ambulatory monitor designed for cardiac arrhythmias detection.Hypothesis: The accuracy of the new SmartCardia wireless patch to detect arrhythmias is comparable to the conventional Holter monitoring.Methods: Patients referred for a suspicion of arrhythmia between February and March 2020 were included in the trial. Simultaneous ambulatory ECG were recorded using a conventional 24-h Holter and the SmartCardia. The primary endpoint was the detection of cardiac arrhythmias over the total wear time of the devices, defined as premature atrial contraction (PAC), supraventricular tachycardia ≥3 beats, premature ventricular contraction (PVC), and ventricular tachycardia ≥3 beats. Conduction abnormalities, pause ≥2 s and atrioventricular block (AVB), were also tracked. McNemar's test was used to compare the matched pairs of data from both devices.Results: A total of 40 patients were included in the trial. Over the total wear time, there was no significant difference between the devices for ventricular and supraventricular arrhythmias detection. Pauses and AVB were equally identified by the two devices in three patients.Conclusion: Over the total wear time, the SmartCardia device showed an accuracy to detect arrhythmia similar to the 24-h Holter monitoring: single-lead, adhesive-patch monitoring might become an interesting alternative to the conventional Holter monitoring.


2021 ◽  
Author(s):  
Martina Patone ◽  
Xue W. Mei ◽  
Lahiru Handunnetthi ◽  
Sharon Dixon ◽  
Francesco Zaccardi ◽  
...  

AbstractAlthough myocarditis and pericarditis were not observed as adverse events in coronavirus disease 2019 (COVID-19) vaccine trials, there have been numerous reports of suspected cases following vaccination in the general population. We undertook a self-controlled case series study of people aged 16 or older vaccinated for COVID-19 in England between 1 December 2020 and 24 August 2021 to investigate hospital admission or death from myocarditis, pericarditis and cardiac arrhythmias in the 1–28 days following adenovirus (ChAdOx1, n = 20,615,911) or messenger RNA-based (BNT162b2, n = 16,993,389; mRNA-1273, n = 1,006,191) vaccines or a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive test (n = 3,028,867). We found increased risks of myocarditis associated with the first dose of ChAdOx1 and BNT162b2 vaccines and the first and second doses of the mRNA-1273 vaccine over the 1–28 days postvaccination period, and after a SARS-CoV-2 positive test. We estimated an extra two (95% confidence interval (CI) 0, 3), one (95% CI 0, 2) and six (95% CI 2, 8) myocarditis events per 1 million people vaccinated with ChAdOx1, BNT162b2 and mRNA-1273, respectively, in the 28 days following a first dose and an extra ten (95% CI 7, 11) myocarditis events per 1 million vaccinated in the 28 days after a second dose of mRNA-1273. This compares with an extra 40 (95% CI 38, 41) myocarditis events per 1 million patients in the 28 days following a SARS-CoV-2 positive test. We also observed increased risks of pericarditis and cardiac arrhythmias following a positive SARS-CoV-2 test. Similar associations were not observed with any of the COVID-19 vaccines, apart from an increased risk of arrhythmia following a second dose of mRNA-1273. Subgroup analyses by age showed the increased risk of myocarditis associated with the two mRNA vaccines was present only in those younger than 40.


2014 ◽  
Vol 129 (3) ◽  
pp. 495-504 ◽  
Author(s):  
Sara Partemi ◽  
Monica Coll Vidal ◽  
Pasquale Striano ◽  
Oscar Campuzano ◽  
Catarina Allegue ◽  
...  

2018 ◽  
Vol 24 ◽  
pp. 202-203
Author(s):  
Mireya Perez-Guzman ◽  
Alfredo Nava de la Vega ◽  
Arturo Pena Velarde ◽  
Tania Raisha Torres Victoria ◽  
Froylan Martinez-Sanchez ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document